The science beneath Rethiamine: pharmacology, nutrition and formulation

Rethiamine™, Reta-B1™ and RetaBone™ are complementary identities for one proprietary Panacea Bio Chem research formulation: 5 mg retatrutide and 20 mg thiamine—vitamin B1—presented as a dual-layer Peptourbillon™ inside the lyophilised chamber of Lyoprester SS™, with a separate 0.5 mL P-EARLs™ reconstitution chamber.

The formulation architecture is deliberate: the retatrutide-containing peptidic liquid is introduced first and frozen as the lower layer; a separately prepared supercooled thiamine liquid is positioned above the frozen retatrutide layer; the two layers are co-lyophilised in the same protected chamber while remaining spatially distinct; and 0.5 mL P-EARLs™ reconstitutes both layers immediately before the single shot. The components are not stored as one ready-mixed liquid.

Rethiamine.com will document the concept, the platform, the development programme and the evidence boundary — what is established in published research and what Panacea is still investigating — as the programme matures.

Between December 2025 and July 2026, Eli Lilly and Company reported five positive phase-3 readouts for retatrutide. TRIUMPH-4 (obesity with knee osteoarthritis) opened the run with -28.7% body weight and -75.8% WOMAC knee-pain reduction at 12 mg/68 weeks. TRIUMPH-1 followed with -28.3% average body weight at 12 mg/80 weeks (efficacy estimand) and -30.3% at 104 weeks in the BMI>=35 extension. TRANSCEND-T2D-1 became the first peer-reviewed phase-3 publication (Lancet 2026): HbA1c -1.94% and weight -15.3% at 12 mg/40 weeks as monotherapy in type 2 diabetes.

In July 2026 the programme completed: TRIUMPH-2 (type 2 diabetes and obesity) showed -20.8% weight at 12 mg/80 weeks, and TRIUMPH-3 (severe obesity with established cardiovascular disease) showed -22.6%. Balanced reporting requires the same prominence for TRIUMPH-3’s cardiovascular outcome: a neutral MACE-3 hazard ratio of 1.12 (95% CI 0.64-1.96). The dedicated cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes (NCT06383390, ~10,000 participants), is fully enrolled and will define the long-term outcomes evidence for the class.

These are company topline announcements except where a peer-reviewed publication is cited; the figures come from sponsor communications pending journal publication. An independent 262-trial BMJ network meta-analysis places retatrutide among the emerging agents with the largest expected weight reductions (13.1-14.6% at one year, very low to low certainty).

Current research has raised concern about nutritional deficiencies during treatment with potent appetite-suppressing incretin therapies, particularly in the presence of severe dietary restriction, nausea or vomiting. Direct retatrutide-induced biochemical depletion of thiamine has not been established. Rethiamine does not assume that retatrutide directly consumes or chemically depletes thiamine — that mechanism has not been established.

What is established: thiamine is required for cellular energy metabolism, humans maintain limited thiamine reserves, and severe restriction of food intake and prolonged vomiting can contribute to thiamine deficiency. A 2026 Nutrients review argues for structured nutritional management, including micronutrient monitoring, during incretin-based therapy — while explicitly not quantifying thiamine deficiency risk on GLP-1/GIP/glucagon agonists and not testing supplementation.

The Panacea hypothesis is one of formulation architecture: retatrutide supplies weekly pharmacological exposure, and Rethiamine investigates whether a thiamine component can be integrated into the same weekly administration event. Whether a weekly thiamine component can meaningfully support thiamine status, and whether the formulation affects retatrutide pharmacokinetics or activity, remain open questions for the development programme. This is a stated hypothesis — no Panacea clinical results exist, and none are claimed.